CXCR4 and ovarian cancer: To evaluate the therapeutic efficacy of Ad5/3-CXCR4-TIMP2 in a clinically relevant in vivo model, we generated orthotopically disseminated ovarian cancer by injecting female nude mice with human SKOV3-luc cells intraperitoneally (i.p.).